[Poly-electrolyte fractionated porcine factor VIII in the treatment of hemophilia A].
In approximately 10 to 15 percent of congenital hemophilia A patients circulating antibodies to factor VIII appear in the blood that poses a serious problem in their treatment. A number of methods and preparations are used in the clinical practice to overcome this problem. Authors report their favourable clinical experience with the administration of polyelectrolyte-fractionated porcine factor VIII. concentrate in a hemophiliac child for the first time in Hungary and a brief review of the clinical methods in use in the management of factor VIII. inhibitors.
Ferencz
T
T
Semmelweis Orvostudományi Egyetem II. Gyermekgyógyászati Klinika, Budapest.
Skopál
J
J
Csáki
C
C
Laczkó
M
M
Schuler
D
D
Borsi
J
J
D000818:Animals; D000906:Antibodies / Q000276:immunology*; D002648:Child; D004573:Electrolytes; D005169:Factor VIII / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000276:immunology; D006467:Hemophilia A / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D008297:Male; D013552:Swine
D000906:Antibodies; D004573:Electrolytes; D005169:Factor VIII
Polielektrolit-frakcionált porcin VIII. faktor egy esetben való alkalmazásáról gátlótestes haemophiliában.